reported lower values of 0.17 and 0.29 for 3-and 12-month study periods, respectively, where all patients were intensively treated and had HbA 1c concentrations maintained at Ͻ7.0%.
Our findings for the five HPLC methods indicated that reproducibility was much less than within-person biological variation. However, the confidence intervals around a measured HbA 1c concentration were still wide (Table 1) in comparison with the small difference (1%) between the ADA HbA 1c management thresholds. The potential impact of measurement uncertainty on HbA 1c thresholds has been discussed previously by Lytken Larsen et al. (17 ) .
The most recently posted results for the College of American Pathologists HbA 1c survey (18 ) show reproducibility values for certified methods between 0.19 and 0.85; the most common method (n ϭ 335), the Abbott IMx (uncertified), had s x ϭ 0.54. Only HPLC methods had s x Ͻ0.25, whereas all multianalyte methods had s x Ն0.43. Minimal analytical performance has been proposed as 0.75s i (19 ) , which based on our results is 0.33. However, the actual DCCT HbA 1c procedure had a repeatability of 0.15 on masked split-duplicate specimens, whereas the long-term internal quality control showed a s a of ϳ0.40 (20 ) .
In summary, the degree of within-person biological variation associated with HbA 1c determinations significantly increases the total measurement error. If a HbA 1c assay of high reproducibility is not used, the dispersion range of true HbA 1c values around the mean true biological set-point will be so wide that the ADA management thresholds may become unworkable. Although the NGSP has significantly reduced intermethod bias, only some HPLC methods currently meet the required analytical performance (19 ) .
A large body of evidence currently documents the utility of the MEGX test for real-time assessment of liver function in transplantation, critical care medicine, and various experimental models (1 ) . The test is based on the conversion of lidocaine to its deethylated metabolite monoethylglycinexylidide (MEGX), primarily through the hepatic cytochrome P450 system. In the standard MEGX test, an intravenous bolus of a small lidocaine dose (1 mg/kg) is administered over 2 min. Blood specimens are collected for serum MEGX determination both before and at 15 and/or 30 min after lidocaine administration. The most commonly used method to measure serum MEGX has been an automated fluorescence polarization immunoasClinical Chemistry 47, No. 10, 2001 say (Abbott Laboratories) with a detection limit of 3 g/L. This test, however, is no longer commercially available. HPLC methods with ultraviolet detection (2, 3 ) and gas chromatographic (GC) procedures with ionization or nitrogen-phosphorous detection (4, 5 ) were originally reported, but all of these techniques had a limit of quantification Ͼ10 g/L. Several studies have shown that transplant candidates with MEGX test results Ͻ10 g/L have a particularly poor 1-year survival rate (6 -8 ) . An improved HPLC method with fluorescence detection (9 ) and a capillary GC method with nitrogen-phosphorus detection (10 ) were therefore developed that achieved an adequate analytical sensitivity with limits of detection of ϳ1-2 g/L. The disadvantage of the HPLC method with fluorescence detection is the necessity to derivatize MEGX.
Because of its flexibility and high specificity, liquid chromatography-tandem mass spectrometry (LC-MS-MS) is finding increasing application for the quantification of numerous analytes. We now describe a reliable, simple, sensitive, and rapid procedure for determining MEGX in serum by LC-MS-MS. This procedure also allows the simultaneous measurement of serum lidocaine concentrations in the same sample.
MEGX hydrochloride and lidocaine hydrochloride were kind gifts from Astra (Stockholm, Sweden). The internal standard monopropylglycinexylidide (MPGX) was synthesized as described previously (9 ) . HPLC-grade methanol and ammonium acetate were obtained from Merck. The calibrator and in-house controls were prepared in drug-free serum (Bio-Rad) from stock solutions of MEGX in deionized water. The final concentration of MEGX in the single-point calibrator was 75 g/L, and the final MEGX concentrations in the four in-house controls were 5, 25, 50, and 125 g/L. To quantify lidocaine, we used a single-point calibrator with a final concentration of 1.1 mg/L and commercial controls (Abbott Laboratories) with final concentrations of 1.5, 3.0, and 7.5 mg/L.
For sample preparation, 100 L of calibrator, qualitycontrol sample, or patient sample was vortex-mixed with 200 L of methanol containing the internal standard MPGX (50 g/L) for 30 s in 1.5-mL polypropylene tubes. After centrifugation for 10 min at 4000g, the supernatants were decanted and, after recentrifugation for 1 min, were placed in a Series 200 autosampler (Perkin-Elmer).
The column was an Oasis ® HLB extraction column A PowerMac personal computer running PE Sciex Sample Control (Ver. 1.4) software was used to control the LC-MS-MS and to record the output signals from the detector. Integration of peak areas, calculation of peakarea ratios, calculation of the calibration line, and calculation of the MEGX concentrations were performed with the PE Sciex TurboQuan TM (Ver. 1.0) software. As a result of the tandem mass spectrometric approach, interference from 3-hydroxy-MEGX (m/z 223.2) or other commonly administered drugs is excluded. The metabolite 3-hydroxy-MEGX, which cross-reacts in the fluorescence polarization immunoassay, is a minor metabolite in humans (11 ) , but it can make a major contribution to lidocaine metabolites in some animal models (12 ) . The lower limit of quantification was set at 1 g/L (CV Ͻ15%; n ϭ 20). The assay was linear over the working range (1-500 g/L; r Ͼ0.9999). To confirm linearity over the working range, drug-free serum was enriched with MEGX from a weighed-in stock solution to final concentrations of 1, 250, and 500 g/L. These samples were then measured in duplicate on 5 separate days, using the single-point calibration. Measured mean (SD) MEGX concentrations were 1.15 (0.1) g/L, 253.1 (12.5) g/L, and 524.7 (25.6) g/L, respectively.
We evaluated the performance characteristics, using the in-house controls prepared by enriching drug-free serum with MEGX to the desired concentration from a stock solution. The four control samples covered the range of MEGX values that are usually encountered in clinical practice (Table 1) . For the within-run imprecision, each control sample was extracted 20 times in one batch. For between-run imprecision, the same four controls were extracted and measured over 8 working days. The analytical recovery was also calculated from the same four controls. The measured values for the in-house control samples were within 5% of the nominal values. The between-and within-run CVs were comparable to those observed for the HPLC-fluorometry method (9 ) . In the case of lidocaine, the within-run imprecision at 1.5, 3.0, and 7.5 mg/L was 4.5%, 3.6%, and 5.4%, respectively. The corresponding recoveries were 98%, 95%, and 91%, respectively. To test the stability of the internal standard (MPGX) and MEGX in the extraction solvent, four samples were extracted with methanol, and the methanolic extracts were stored at ambient temperature (ϳ20°C) in closed vials for 3 days. The differences between the stored samples and the samples that were measured immediately averaged 1%. The effect of storage at 4°C on the stability of MEGX in serum was tested with 10 patient samples (MEGX concentration, 21-75 g/L). When we reanalyzed the samples after 9 days, there was good correlation between the initial and stored sample values (r 2 ϭ 0.99; Passing-Bablok regression line, y ϭ 1.02x Ϫ 1.06). The differences between the stored samples and the samples that were measured immediately averaged 0.08 g/L (95% confidence interval, Ϫ1.11 to 1.28 g/L).
To investigate ion suppression, we performed the following experiments. Five MEGX-free serum samples from five patients with hyperbilirubinemia (bilirubin Ͼ342 mol/L) and five patients with bilirubin values Ͻ20.5 mol/L were extracted with methanol as described above. The methanolic extracts were then enriched with MEGX (final nominal concentration, 30 g/L) and internal standard (MPGX) from a stock solution. Reference methanolic solutions containing the same nominal concentrations of MEGX and MPGX were also prepared. The extracts and reference solutions were injected onto the analytical column, and the peak areas for MEGX and MPGX were compared. The mean (SD) ratio of the serum extract peak area to the reference peak area was 0.41 (0.05) for the internal standard and 0.44 (0.06) for MEGX. Thus, although ion suppression occurred, the extent of this suppression was similar for the internal standard and MEGX. No differences were observed between the hyperand normobilirubinemic samples.
We analyzed 106 serum samples (from sampling time points at 15 and 30 min) from 53 patients who were routinely undergoing the MEGX test by the LC-MS-MS method and by the HPLC-fluorometry procedure. A method difference plot (Fig. 1) revealed good agreement between both methods over the clinically relevant range of MEGX concentrations. The mean absolute difference between the two methods was Ϫ0.6 g/L. The equation for the Passing-Bablok regression line was: y ϭ 0.9845x ϩ 1.6784 (r 2 ϭ 0.96; 95% median distance of the residuals of the Passing-Bablok regression, 6.02 g/L). The relative difference between the two methods tended to be greater at MEGX concentrations Ͻ20 g/L, which probably reflects the greater between-run imprecision of the two methods in the low MEGX range. However, these differences were not of major clinical relevance. The LC-MS-MS concentrations for the four samples whose values were outside the 95% confidence interval were confirmed by repeat analysis. There was insufficient material to repeat the measurements with the HPLC-fluorometry procedure.
In conclusion, the LC-MS-MS method described here for measurement of MEGX in serum samples is rapid, reproducible, specific, and requires only a small sample volume (100 L). The procedure offers substantial advantages over available methods with a comparable limit of quantification. The HPLC-fluorometry (9 ) and capillary GC (10 ) methods require sample volumes of 0.5 and 1.0 mL, respectively, to achieve a similar analytical sensitivity. The analysis time for the LC-MS-MS is also considerably shorter (3 min) than those (ϳ10 -15 min) of the HPLC-fluorometry and capillary GC methods. Furthermore, sample preparation for LC-MS-MS is much simpler than that required for the other two methods. The technician time to process 30 samples is ϳ0.5 h. The LC-MS-MS procedure also has the advantage that serum lidocaine concentrations can be measured concomitantly in the same sample to confirm that an appropriate lidocaine dose was used for the MEGX test. In our experience, serum lidocaine concentrations 15 min after a lidocaine dose of 1 mg/kg range from 0.4 to 3.5 mg/L in patients undergoing the MEGX test. Thus, despite the high initial capital cost, this LC-MS-MS procedure is an attractive and cost-effective alternative to existing methods. (1 ) first described the presence of fetal DNA in maternal plasma and serum. Cell-free DNA offered a new source of fetal genetic material for noninvasive prenatal diagnosis. They developed a real-time, quantitative PCR assay to measure the concentration of fetal DNA and analyzed SRY, a single-copy Y-chromosome-specific sequence, to quantify the number of genome-equivalents per milliliter of blood when a woman carries a male fetus (2 ) . The results revealed that the concentrations of fetal DNA in maternal plasma DNA during the first and third trimesters were 3.4% and 6.2%, respectively. They estimated a mean of 25.4 copies of fetal DNA circulates per milliliter of maternal plasma samples during early pregnancy. They also demonstrated that after delivery, cell-free fetal DNA is cleared very rapidly from the maternal circulation, with a half-life in the order of minutes (3 ) . Thus, the relatively high concentration of fetal cell-free DNA suggests that extensive and timeconsuming fetal DNA enrichment procedures would not be necessary when using fetal DNA from maternal plasma for diagnostic purposes.
Although the potential of fetal cell-free DNA analysis for the prenatal diagnosis of fetal gender (2 ) and rhesus D status (4, 5 ) has been presented, the accuracy of prenatal diagnosis has not been described. If fetal gender could be determined, the number of invasive procedures required to determine X-linked genetic disorders would be reduced. The present study evaluated the diagnostic accuracy of fetal gender determination using cell-free DNA from maternal plasma obtained at early gestation.
Pregnant women (n ϭ 302), carrying a single fetus between 7 and 16 weeks of gestation, who attended Showa University Hospital between February 1999 and September 2000 gave their written informed consent to participate in this study. Approval for this study was obtained from the ethics committee of the university. None of the women had vaginal bleeding. Fetal heart movements were detected in all of the women by transvaginal ultrasonography.
Maternal blood samples (10 mL) collected into tubes containing EDTA were separated by centrifugation at 3000g within 3 h. Plasma was transferred into plain polypropylene tubes and again separated by centrifugation at 3000g. The supernatant was collected into fresh tubes and stored at Ϫ20°C until further processing.
DNA was extracted from 1.5 mL of plasma samples using QIAamp Blood Mini Kit (Qiagen) according to the "blood and body fluid protocol" with minor modifications. DNA was eluted from columns with 50 L of water.
Although a real-time quantitative PCR assay using an ABI PRISM 7700 Sequence Detector (Applied Biosystems) for maternal plasma DNA analysis has been reported by several investigators (2, 4, 6, 7 ) , we used a LightCycler (Roche Diagnostics), which is a reliable method of DNA quantification (8 ) . The Y-chromosome-specific sequence, DYS-14, in male fetuses was used as a molecular marker to quantify fetal cell-free DNA (9 ) . The PCR system for the DYS-14 sequence consisted of the amplification primers DYS14-713F (5Ј-CAT CCA GAG CGT CCC TGG-3Ј) and DYS14-880R (5Ј-TTC CCC TTT GTT CCC CAA A-3Ј) and the dual-labeled fluorescent probe DYS14-883T (5Ј-FAM-CGA AGC CGA GCT GCC CAT CA-TAMRA-3Ј). The fluorogenic PCR reactions were prepared according to the manufacturer's instructions in a reaction volume of 20 L with all components except the fluorescent probe and amplification primers obtained from a reagent set (LightCycler-Fast Start DNA Master Hybridization Probes; Roche Diagnostics). The extracted plasma DNA (13.1 L) was used as a template for each reaction. Thermal cycling was initiated with denaturation at 95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 10 s, annealing at 57°C for 20 s, and extension at 72°C for 20 s. The number of copies of male DNA present in the plasma sample was determined by comparison with a calibration dilution curve of male genomic DNA. The number of copies used for conversion was 6.6 pg, as described previously (2 ) .
Amplification data were analyzed using LightCycler
